China Pharma (NYSE:CPHI) Stock Rating Upgraded by StockNews.com

China Pharma (NYSE:CPHI) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

China Pharma Price Performance

Shares of NYSE CPHI opened at $2.35 on Wednesday. China Pharma has a twelve month low of $1.20 and a twelve month high of $3.39. The company has a debt-to-equity ratio of 0.22, a quick ratio of 0.26 and a current ratio of 0.79. The company has a 50 day moving average of $11.48 and a 200 day moving average of $17.66.

China Pharma Company Profile

China Pharma Holdings, Inc develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People’s Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions.